BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Metabomed Ltd.

Headquarters: Yavne, Israel
Website: N/A
Year Founded: 2013
Status: Out of Business

BioCentury | Sep 27, 2023
Discovery & Translation

Targeting ACSS2 in solid tumors; plus a multi-lab preclinical trial and more

BioCentury’s roundup of translational innovation
BioCentury | Apr 24, 2020
Emerging Company Profile

FoRx: A broader look at DNA damage repair

FoRx is using synthetic lethality to attack a broad set of cancers with new DNA damage repair targets
BioCentury | Jun 22, 2017
Emerging Company Profile

Repare in progress

Synthetic lethality play Repare emerges from stealth with $68M series A
BioCentury | Mar 31, 2017
Finance

It takes two

Tango joins synthetic lethality crowd with $55M series A from Third Rock
BioCentury | Apr 11, 2016
Financial News

Metabomed financial update

BioCentury | Apr 5, 2016
Financial News

Metabomed caps $18M series A

BioCentury | Dec 9, 2013
Financial News

Metabomed completes venture financing

BioCentury | Nov 27, 2013
Financial News

Merck Serono's Israeli incubator debuts two newcos

Items per page:
1 - 8 of 8